Translate
Translate this website into the following languages:



Close Tab
Donations
UC San Diego Health
menu iconMenu
search iconSearch

Clinical Trials at Sanford Stem Cell Clinical Center

CIRM Alpha Stem Clinic at UC San Diego Health

Spinal Cord Injury

Researchers at UC San Diego are collaborating with Neuralstem, Inc. to conduct the safety trial of neural stem cell transplantation in paralysis patients due to traumatic injury within spinal cord segments T2-T12.

The transplantation involves the injection of nueral stem cells into the spinal cord. This first in human clinical trial evaluates the safety of transplanting neural stem cells into the spine.

More Information

To learn about eligibility for this clinical trial, please call the Alpha Stem Cell Clinic (844) 317-STEM (7836) or e-mail alphastemcellclinic@ucsd.edu.

 Chronic Lymphocytic Leukemia

Researchers at UC San Diego are conducting the Phase 1 clinical trial of the intravenous infusion of an antibody that targets cancer stem cells in people with relapsed or refractory chronic lymphocytic leukemia (CLL).

This antibody, developed at UC San Diego, is designed to attach to a protein, called ROR1, on the surface of CLL cells to block cell growth and survival. This first in human trial evaluates whether the intravenous infusion is safe and well-tolerated.

More Information

To learn about eligibility for this clinical trial, please call Jesika Reiner at (858) 822-5364 or e-mail jreiner@ucsd.edu.

Type 1 Diabetes

Researchers at UC San Diego are collaborating with ViaCyte, Inc. to conduct the Phase 1/2 clinical trial of a stem cell-derived therapy for people who have had type 1 diabetes for at least 3 years and are on stable diabetic treatment.

The therapy involves the implantation of a device containing cells under the skin. This first in human clinical trial evaluates the safety of the combination product.

More Information

To learn about eligibility for this clinical trial, please call the Alpha Stem Cell Clinic (844) 317-STEM (7836) or e-mail alphastemcellclinic@ucsd.edu.

Chronic Heart Failure

Researchers at UC San Diego are collaborating with Teva Pharmaceutical Industries Ltd. to conduct the Phase 3 clinical trial of bone marrow-derived precursor stem cell transplantation in people with chronic heart failure of ischemic or nonischemic etiology for at least six months.

This study evaluates the effectiveness of transplanting bone marrow-derived allogeneic mesenchymal precursor cells (MPCs) into people with chronic heart failure.

More Information

To learn about eligibility for this clinical trial, please call Teva US Medical Information at 1 (800) 896-5855.

Our bimonthly newsletter delivers healthy lifestyle tips, patient stories and research discovery news. Subscribe: